Article
Tom Caravela
How MSLs can WIN with Social Media in Medical Affairs
Summary
In this episode, Tom Caravela is joined by Bruno Larvol to explore the intersection of medical science liaisons (MSLs) and social media. They discuss the importance of social media engagement, addressing compliance concerns, and the value of social media listening for MSLs. The conversation includes strategies for leveraging social media insights, building a professional brand, and distinguishing between key opinion leaders and digital opinion leaders. Bruno and Tom also delve into social media's impact on recruitment, career development, and time allocation, while promoting progressive engagement policies. The episode concludes with insights on the future of podcasting and the metaverse.
My guest today is Bruno Larvol, CEO and Founder at Larvol, we discuss how Medical Science Liaisons should be using Social Media in their career
_This episode is sponsored by Larvol, Established in 2004, LARVOL combines the best of artificial and human intelligence to deliver expertly curated and personalized data solutions to medical affairs, competitive intelligence, commercial, and R&D teams within the pharmaceutical and biotech industry. For more details, please visit www.larvol.com
_Bruno discusses….
👉 How MSLs should be using Social Media and on what platforms
👉 What risks are involved for MSLs when it comes to Social Media
👉 Best practices for career development and Social Media
👉 Posting methods MSLs should be considering
👉 Social listening and why it is a mandatory for MSLs
Medical Science Liaisons, Social Media Engagement, Compliance Concerns, Professional Brand, Social Media Listening
Related Topics
You May Also Like
Tom Caravela
Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Social Media Listening Evolved
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Article
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy